JP2025516543A - がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ - Google Patents

がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ Download PDF

Info

Publication number
JP2025516543A
JP2025516543A JP2024566197A JP2024566197A JP2025516543A JP 2025516543 A JP2025516543 A JP 2025516543A JP 2024566197 A JP2024566197 A JP 2024566197A JP 2024566197 A JP2024566197 A JP 2024566197A JP 2025516543 A JP2025516543 A JP 2025516543A
Authority
JP
Japan
Prior art keywords
methyl
indazol
combination according
combination
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516543A5 (enExample
Inventor
ゲオルク ジェスキー，
ブルーノ マルトリオ，
イヴォン アリス ナーゲル，
クリスタ ウルリケ オブスト－サンダー，
アントニオ リッチ，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2025516543A publication Critical patent/JP2025516543A/ja
Publication of JP2025516543A5 publication Critical patent/JP2025516543A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024566197A 2022-05-13 2023-05-11 がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ Pending JP2025516543A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22173211.8 2022-05-13
EP22173211 2022-05-13
EP22175302 2022-05-25
EP22175302.3 2022-05-25
PCT/EP2023/062530 WO2023217924A1 (en) 2022-05-13 2023-05-11 Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025516543A true JP2025516543A (ja) 2025-05-30
JP2025516543A5 JP2025516543A5 (enExample) 2026-05-18

Family

ID=86558741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566197A Pending JP2025516543A (ja) 2022-05-13 2023-05-11 がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ

Country Status (9)

Country Link
US (1) US20260007678A1 (enExample)
EP (1) EP4522113A1 (enExample)
JP (1) JP2025516543A (enExample)
KR (1) KR20250009977A (enExample)
CN (1) CN119173253A (enExample)
AU (1) AU2023268579A1 (enExample)
CA (1) CA3255503A1 (enExample)
TW (1) TW202408534A (enExample)
WO (1) WO2023217924A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (en) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Egfr inhibitors for the treatment of cancer
WO2022117475A1 (en) 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (en) * 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Egfr inhibitors for the treatment of cancer
WO2022117487A1 (en) * 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives
US20240002390A1 (en) * 2020-12-01 2024-01-04 Hoffmann-La Roche Inc. New indazole acetylene derivatives
WO2022117475A1 (en) * 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag New indazole derivatives

Also Published As

Publication number Publication date
TW202408534A (zh) 2024-03-01
EP4522113A1 (en) 2025-03-19
US20260007678A1 (en) 2026-01-08
AU2023268579A1 (en) 2024-09-19
CN119173253A (zh) 2024-12-20
CA3255503A1 (en) 2023-11-16
WO2023217924A1 (en) 2023-11-16
KR20250009977A (ko) 2025-01-20

Similar Documents

Publication Publication Date Title
JP7530391B2 (ja) がんの治療のためのｅｇｆｒ阻害剤
JP7561779B2 (ja) 新規ｅｇｆｒ阻害剤
EP3735299B1 (en) Fused ring compounds
US20220281893A1 (en) Tetracyclic oxazepine compounds and uses thereof
JP2020502246A (ja) ２−ベンゾピラジニル−ｎ−ヘテロアリール−２−フェニル−アセトアミド化合物
JP7701360B2 (ja) Ｅｇｆｒ阻害剤
KR20250009977A (ko) 암 치료를 위한 알로스테릭 및 오르토스테릭 egfr 억제제의 조합물
TW202237611A (zh) 新穎吲唑乙炔衍生物
JP2025515833A (ja) 新規インダゾール誘導体
TW202342461A (zh) 雜環化合物及使用方法
WO2023209090A1 (en) Bicyclic heteroaromatic compounds and their application in the treatment of cancer
HK40115468A (zh) 用於治疗癌症的变构和正构egfr抑制剂的组合产品
RU2853003C1 (ru) Новые индазолацетиленовые производные
RU2783706C1 (ru) Соединения с конденсированными кольцами
HK40071776A (en) Egfr inhibitors
HK40063822A (en) Egfr inhibitor for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260508